Tag: Rituximab

Infusion-related reactions are a very common side effect of rituximab, with some studies showing up to 77% of patients experiencing a reaction during their first infusion. This article explores the question, 'What are the most common adverse effects of rituximab?'.

According to clinical data, most infusion-related side effects with Rituxan occur within 30 to 120 minutes of the first infusion and are typically mild and temporary. However, the duration of Rituxan side effects varies significantly depending on the type of reaction, with some symptoms resolving within hours while others can persist for weeks, months, or even longer.

Biosimilars generally cost 15% to 45% less than the originator biologic, making it highly likely that **is Truxima cheaper than rituximab?** Yes, it is, and this article explains why these cost savings are so crucial for patients and the healthcare system. Approved in 2018 as the first rituximab biosimilar, Truxima (rituximab-abbs) was launched with a significant discount compared to the brand-name Rituxan.

The biologic drug Rituxan® was first approved by the FDA in 1997, and its generic name is rituximab. This monoclonal antibody has become a cornerstone therapy for various cancers and autoimmune conditions, with several biosimilar versions now available to offer patients more affordable options.

As of 2023, there are three FDA-approved biosimilars for Rituxan (rituximab) available in the United States, offering alternatives for patients and healthcare providers [1.5.3]. If you're asking, 'What is a substitute for RITUXAN?', it's important to understand these biosimilars and other therapeutic options.

In clinical trials for non-Hodgkin's lymphoma, the median time to response was approximately 50 days (about 7 weeks) following a Rituxan infusion. However, the answer to how long does it take for a Rituxan infusion to work varies significantly depending on the treated condition, with some patients noticing improvement much later.

Infusion-related reactions are a very common side effect of Rituxan, with some studies showing they occur in over 80% of patients during the first infusion [1.6.5]. So, what is the most common side effect of Rituxan and what should patients expect?

First approved by the FDA in 1997 for certain lymphomas, rituximab is a medication widely known for its efficacy across various hematologic cancers and autoimmune disorders, leading many to ask: **what class of drug is rituximab infusion**?. It is classified as a monoclonal antibody, a type of targeted therapy that works by harnessing the body's own immune system to fight disease.

The U.S. Food and Drug Administration (FDA) first approved Truxima (rituximab-abbs) in 2018 as a biosimilar to Rituxan [1.3.1]. This raises a critical question for patients and providers: Is Truxima as good as Rituxan? This article examines the evidence.

The first Rituxan infusion typically takes 4 to 6 hours or even longer, primarily due to the slow infusion rate to monitor for potential reactions. Understanding **how long do Rituxan infusions last?** is crucial for proper treatment planning, as subsequent sessions are often significantly shorter.